Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Global Pharma and Biotech Summit

The Global Pharma and Biotech Summit is a must-attend event for anyone looking to stay ahead of life sciences trends and innovations. With 300+ attendees [...]

Go to Top